Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.

“We are thrilled to be working with the high caliber global team of sanofi-aventis, and look forward to successful research collaboration”

“We are thrilled to be working with the high caliber global team of sanofi-aventis, and look forward to successful research collaboration,” said Hans A Petersen, President and CEO of Traversa. “This agreement will allow sanofi-aventis to select lead RNAi candidates and provide Traversa with a better understanding of the strengths of our RNAi delivery technology. We are excited to be working with sanofi-aventis to conduct this research, and hope to advance the treatments selected during this collaboration into IND-enabling studies and into the clinics.”

Traversa Therapeutics and sanofi-aventis